Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors April 30, 2021 FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment July 7, 2020 FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... February 4, 2026 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 Load more HOT NEWS To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe Exosomes May Help Tumors Evade Immune System The Power of Fruits and Vegetables
